Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
Clinical trial NCT00617253 · COMPLETED
Trial details
- NCT number
- NCT00617253
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-07-12
- Primary completion
- 2008-06-30
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.